Janux Therapeutics (NASDAQ:JANX) Shares Down 4.6%

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) traded down 4.6% on Tuesday . The company traded as low as $39.22 and last traded at $39.79. 245,485 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 802,316 shares. The stock had previously closed at $41.72.

Wall Street Analyst Weigh In

Several research analysts have recently commented on JANX shares. Jonestrading started coverage on Janux Therapeutics in a report on Tuesday, April 16th. They set a “buy” rating and a $70.00 price target on the stock. Wedbush lifted their price target on Janux Therapeutics from $53.00 to $74.00 and gave the stock an “outperform” rating in a report on Wednesday, May 8th. HC Wainwright lifted their price target on Janux Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, May 13th. Scotiabank started coverage on Janux Therapeutics in a report on Thursday, May 30th. They set a “sector perform” rating and a $47.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, May 9th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $66.29.

Janux Therapeutics Trading Down 2.0 %

The business has a 50-day moving average of $47.24 and a 200-day moving average of $32.62.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%. Analysts predict that Janux Therapeutics, Inc. will post -1.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of Janux Therapeutics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $37,081,025.25. Following the completion of the transaction, the insider now directly owns 3,271,216 shares of the company’s stock, valued at approximately $179,099,076. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO Tighe Reardon sold 822,721 shares of Janux Therapeutics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the completion of the transaction, the chief financial officer now owns 633,673 shares in the company, valued at approximately $34,693,596.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $37,081,025.25. Following the sale, the insider now owns 3,271,216 shares of the company’s stock, valued at approximately $179,099,076. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,000,000 shares of company stock valued at $164,250,000. 35.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors have recently added to or reduced their stakes in JANX. Nisa Investment Advisors LLC lifted its stake in Janux Therapeutics by 10,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after purchasing an additional 2,685 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Janux Therapeutics during the fourth quarter worth approximately $57,000. SG Americas Securities LLC purchased a new stake in Janux Therapeutics during the fourth quarter worth approximately $100,000. Exchange Traded Concepts LLC lifted its stake in Janux Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company’s stock worth $152,000 after purchasing an additional 3,602 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Janux Therapeutics during the first quarter worth approximately $251,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.